Alterity Therapeutics Limited - Depositary Receipt (Common Stock)

Alterity Therapeutics Limited - Depositary Receipt (Common Stock) represents ownership in Alterity Therapeutics Limited, an Australia-based clinical-stage biotechnology company. The company focuses on developing disease-modifying treatments for neurodegenerative conditions, including Parkinson's disease, Dementia with Lewy bodies, Multiple System Atrophy, Alzheimer's disease, and Huntington's disease. Its lead product candidate, ATH434, comprises molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. Alterity Therapeutics also advances PBT2 and maintains a drug discovery platform to generate chemicals that intervene in disease processes. Operating within the pharmaceuticals and biotech sector, it conducts research and development of therapeutic drugs targeting neurological disorders. Founded in 1997 and headquartered in Melbourne, Australia, Alterity Therapeutics plays a specialized role in advancing innovative therapies for unmet medical needs in neurodegeneration.